PeptiDream entered into a collaboration and license agreement with Eli Lilly and Company to identify macrocyclic peptides as potential drug candidates for disease targets being pursued by Lilly. PeptiDream will leverage its Peptide Discovery Platform System (PDPS) technology for translational synthesis, selection, and screening of nonstandard macrocyclic peptides, and Lilly will be responsible for any subsequent research and development as pharmaceutical candidates.
As part of the agreement, PeptiDream will receive an undisclosed upfront payment, research funding, and milestone payments upon the successful achievement of certain development milestones. PeptiDream is also eligible to receive royalties on future sales of products that arise from the collaboration.
This is not the first pharma giant PeptiDream has collaborated with this year. In September, the company agreed to nonexclusively license its PDPS technology to Bristol-Myers Squibb in addition to extending a nearly three-year-old macrocyclic peptide drug discovery alliance.
